Incyte Corp. Company Profile (NASDAQ:INCY)

About Incyte Corp.

Incyte Corp. logoIncyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INCY
  • CUSIP: 45337C10
Key Metrics:
  • Previous Close: $88.49
  • 50 Day Moving Average: $87.67
  • 200 Day Moving Average: $82.11
  • 52-Week Range: $188,002,000.00 - $55.00
  • Trailing P/E Ratio: 238.37
  • Foreward P/E Ratio: 62.66
  • P/E Growth: 9.09
  • Market Cap: $16.49B
  • Outstanding Shares: 188,002,000
  • Beta: 0.54
  • Net Margins: 7.87%
  • Return on Equity: 37.76%
  • Return on Assets: 6.64%
  • Debt-to-Equity Ratio: 2.14%
  • Current Ratio: 3.98%
  • Quick Ratio: 3.95%
Additional Links:
Companies Related to Incyte Corp.:

Analyst Ratings

Consensus Ratings for Incyte Corp. (NASDAQ:INCY) (?)
Ratings Breakdown: 20 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $106.50 (21.41% upside)

Analysts' Ratings History for Incyte Corp. (NASDAQ:INCY)
DateFirmActionRatingPrice TargetDetails
10/12/2016RBC Capital MarketsSet Price TargetBuy$113.00View Rating Details
10/12/2016Leerink SwannReiterated RatingOutperform$98.00View Rating Details
10/12/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
10/12/2016Royal Bank Of CanadaBoost Price TargetOutperform$106.00 -> $113.00View Rating Details
10/10/2016JMP SecuritiesBoost Price TargetMarket Outperform$100.00 -> $110.00View Rating Details
10/7/2016BMO Capital MarketsBoost Price TargetOutperform$100.00 -> $121.00View Rating Details
9/28/2016Piper Jaffray Cos.Set Price TargetBuy$99.00View Rating Details
9/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
9/29/2016Raymond James Financial Inc.UpgradeMarket Perform -> Outperform$115.00View Rating Details
9/26/2016ArgusBoost Price TargetBuy$92.00 -> $98.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$98.00View Rating Details
8/10/2016Barclays PLCBoost Price TargetOverweight$85.00 -> $100.00View Rating Details
8/5/2016SunTrust Banks Inc.Initiated CoverageBuy$105.00View Rating Details
6/29/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details
5/19/2016Morgan StanleyReiterated RatingBuyView Rating Details
5/10/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
1/31/2016Bank of America Corp.Reiterated RatingBuy$145.00 -> $87.00View Rating Details
1/19/2016Credit Suisse Group AGInitiated CoverageOutperform$110.00View Rating Details
11/19/2015UBS AGReiterated RatingBuy$130.00View Rating Details
10/6/2015NomuraBoost Price TargetBuy$126.00 -> $146.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Incyte Corp. (NASDAQ:INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.05)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.09)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3($0.06)$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214$0.05($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.17)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corp. (NASDAQ:INCY)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $1.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.02$0.34$0.14
Q2 20164($0.06)$0.03($0.02)
Q3 20164($0.06)$0.03($0.01)
Q4 20164($0.10)$0.02($0.05)
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corp. (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Incyte Corp. (NASDAQ:INCY)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 92.38%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Incyte Corp. (NASDAQ:INCY)
News IconIncyte Corporation Pipeline Review, Industry Study, Research and Clinical trial 2016 – 2020 (NASDAQ:INCY) - October 23 at 10:01 AM
News IconOwnership Action To Observe: Incyte Corp (NASDAQ:INCY ... - Post News (NASDAQ:INCY) - October 22 at 9:47 AM logoEli Lilly and Co.’s 3Q16: The Major Developments (NASDAQ:INCY) - October 21 at 5:42 PM
News IconHot Biotech Stocks Recap: Incyte Corporation (NASDAQ:INCY), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - The Voice Registrar (NASDAQ:INCY) - October 20 at 11:12 AM
News IconIncyte Corp.'s (INCY) “Outperform” Rating Reiterated at Leerink Swann - DailyQuint (NASDAQ:INCY) - October 20 at 11:12 AM logoAbbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View (NASDAQ:INCY) - October 19 at 5:57 PM
News IconTop Gainers of the Day: Incyte Corporation (NASDAQ:INCY) from Biotechnology (NASDAQ:INCY) - October 19 at 10:31 AM logoRoche's Tecentriq Wins FDA Nod for Additional Indication (NASDAQ:INCY) - October 19 at 10:31 AM
News IconUpdate on Incyte Corporation (NASDAQ:INCY) for the day (NASDAQ:INCY) - October 18 at 10:46 AM logoNasdaq 100 Movers: INCY, MAT (NASDAQ:INCY) - October 17 at 10:39 AM logoBristol-Myers Wins CHMP Nod for Opdivo Label Expansion (NASDAQ:INCY) - October 17 at 10:39 AM logoCelgene to Present Phase Ib Data on Crohn's Disease Drug (NASDAQ:INCY) - October 17 at 10:39 AM
News IconLeading stocks in today’s market: Incyte Corporation (NASDAQ:INCY) (NASDAQ:INCY) - October 16 at 10:07 AM
News IconHigh Market Cap Stock of the Day – Incyte Corporation (NASDAQ:INCY) (NASDAQ:INCY) - October 14 at 8:48 AM logoIncyte to Report Third Quarter Financial Results (NASDAQ:INCY) - October 14 at 8:48 AM
News IconIncyte Corp. (INCY) Given New $110.00 Price Target at JMP Securities - DailyQuint (NASDAQ:INCY) - October 13 at 5:40 PM
News IconIncyte Corp. (INCY) EVP Barry P. Flannelly Sells 24204 Shares (NASDAQ:INCY) - October 13 at 8:56 AM
News IconIncyte Corp. (INCY) Receives $104.09 Consensus Price Target from Analysts (NASDAQ:INCY) - October 13 at 8:56 AM
News IconIncyte Corp. (INCY) Given Outperform Rating at Leerink Swann (NASDAQ:INCY) - October 13 at 8:56 AM
News IconIncyte Corporation (NASDAQ:INCY) Ratings Coverage (NASDAQ:INCY) - October 12 at 10:45 AM
News IconBiotech news that matter for investors: Incyte Corporation (NASDAQ:INCY), Vertex Pharmaceuticals Incorporated ... - The Voice Registrar (NASDAQ:INCY) - October 11 at 5:49 PM logo3 Biotechs Most Likely to Be Acquired (NASDAQ:INCY) - October 11 at 12:42 PM
News IconMix Wondering Stocks- Exelixis (NASDAQ:EXEL), Incyte ... - Seneca Globe (NASDAQ:INCY) - October 10 at 10:17 AM
News IconNoteworthy Analyst Ratings of Two Stocks Incyte Corporation ... - The Voice Registrar (NASDAQ:INCY) - October 10 at 10:17 AM logoCan the Rally in Incyte (INCY) Shares Continue? (NASDAQ:INCY) - October 10 at 10:17 AM logoStock Update (NASDAQ:INCY): Incyte Corporation Presents Updated Data from Epacadostat at ESMO 2016 (NASDAQ:INCY) - October 9 at 10:01 AM logoBRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial - Reuters (NASDAQ:INCY) - October 7 at 5:28 PM
News IconAdditional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastati... (NASDAQ:INCY) - October 7 at 10:38 AM logoAdditional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination ... (NASDAQ:INCY) - October 7 at 10:38 AM logoThese Are the Fastest Growing Profitable Biotech Stocks (NASDAQ:INCY) - October 7 at 10:38 AM logoBRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial (NASDAQ:INCY) - October 7 at 5:07 AM
News IconTrading the Biotech News: Illumina Inc. (NASDAQ:ILMN), Incyte Corporation (NASDAQ:INCY) - The Voice Registrar (NASDAQ:INCY) - October 6 at 5:31 PM
News IconTrading the Biotech News: Illumina Inc. (NASDAQ:ILMN), Incyte Corp. (NASDAQ:INCY) - The Voice Registrar (NASDAQ:INCY) - October 6 at 5:31 PM
News IconStock of The Day: Institutional Investors Positive on Incyte Corp (NASDAQ:INCY) - Post News (NASDAQ:INCY) - October 6 at 11:00 AM
News IconPay Close Attention To These Analyst Ratings Incyte Corporation (NASDAQ:INCY), Bristol-Myers Squibb Co (NYSE:BMY) - The Voice Registrar (NASDAQ:INCY) - October 4 at 10:24 AM
News IconCommit To Purchase Incyte Corporation At $67.50, Earn 8.2% Using Options (NASDAQ:INCY) - October 3 at 5:21 PM
News IconIncyte Corporation (NASDAQ:INCY) from Biotechnology – Todays Top Gains (NASDAQ:INCY) - October 3 at 10:14 AM logoIncyte Corporation (NASDAQ:INCY) Mean Price Target At $100.545 (NASDAQ:INCY) - September 30 at 5:52 PM
News IconBiotechnology: Incyte Corporation (NASDAQ:INCY) Position of the day (NASDAQ:INCY) - September 30 at 5:52 PM logoWhat Will Gilead Try Buying Next? Polls Offer Some 'Incyte' (NASDAQ:INCY) - September 30 at 5:52 PM logoWhat Will Gilead Try Buying Next? Polls Offer Some 'Incyte' (NASDAQ:INCY) - September 30 at 5:52 PM
News IconHot Biotech Stocks Recap: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Incyte Corporation (NASDAQ:INCY) - The Voice Registrar (NASDAQ:INCY) - September 30 at 10:47 AM
News IconBroker Roundup For Incyte Corporation (NASDAQ:INCY) - The De Soto Edge (NASDAQ:INCY) - September 29 at 5:35 PM
News IconNoteworthy Analyst Ratings of Two Stocks Western Digital Corp (NASDAQ:WDC), Incyte Corporation (NASDAQ:INCY) - The Voice Registrar (NASDAQ:INCY) - September 29 at 5:35 PM logoStock Update (NASDAQ:INCY): Incyte Corporation Announces ... - Smarter Analyst (NASDAQ:INCY) - September 29 at 5:35 PM logoNCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis - Business Wire (press release) (NASDAQ:INCY) - September 29 at 5:35 PM logoIncyte upgraded by Raymond James (NASDAQ:INCY) - September 29 at 5:35 PM logoStreet Talk: INCY, EBAY & more (NASDAQ:INCY) - September 29 at 5:35 PM logoIncyte Gains as Melanoma Combo Sees Success in Early-Stage Trial (NASDAQ:INCY) - September 29 at 10:43 AM
News IconBroker Roundup For Incyte Corporation (NASDAQ:INCY) (NASDAQ:INCY) - September 29 at 10:43 AM


Incyte Corp. (NASDAQ:INCY) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff